CYP19 Genetic Polymorphism & Aromatase Inhibitor(AI)

Launched by KOREA UNIVERSITY ANAM HOSPITAL · Sep 8, 2009

Keywords

ClinConnect Summary

No description provided

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 1. The patient must sign the informed consent.
• • 2. The patient must sign the informed consent of genetic screening test.
• • 3. The patient must be between 18 years old and 80 years old who can make a decision independently.
• • 4. The patient must be post-menopause status.
• • 5. The patient should be the stage 1,2 or 3 of the breast cancer.
• • 6. The test result of the estrogen receptor or progesterone receptor is positive, so the patient should be taking the medication of AI (Aromatase Inhibitor).
• Exclusion Criteria:
• • 1. The patient is pre-menopause status.
• • 2. The test result of serum FSH level is below 30mU/ml.
• • 3. The test result of the hormone receptor(ER \& PR) is negative or unknown.
• • 4. Patient's breast cancer stage is 4 which has systemic metastatics.